Serum metabolite differences detected by HILIC UHPLC-Q-TOF MS in systemic sclerosis

Sun, Cheng; Zhu, Hao; Wang, Yun; Han, Yichen; Zhang, Dongdong; Chen, Xi; Alip, Mihribangvl; Nie, Min; Xue, Xiangxin; Lv, Liangjing; Feng, Xuebing; Sun, Lingyun; Wang, Dandan

doi:10.1007/s10067-022-06372-z

Cited by 5 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, patients with SSc should be screened for PAH, even if asymptomatic, by cardiac echocolordoppler, respiratory testing, and NT-ProBNP assay. Diagnostic algorithms have been proposed to identify patients for RHC, which is still the gold standard tool for diagnosing PAH and PH [116][117][118][119][120][121][122][123][124][125][126]. Risk factors for PAH include severe Raynaud's phenomenon, severe digital ischemia, cutaneous telangiectasias, chronic disease, late onset of the disease, advanced age, postmenopausal status, reduced diffusing capacity (DLCO < 50%), DLCO/alveolar volume less than 70%, forced vital capacity/DLCO less than 1.6, and increased right ventricular systolic pressure greater than 2 mmHg/year [110][111][112][113][114][115][116][117][118][119].…”

Section: Biomarkers In Systemic Sclerosis Vascular Injury Focus On Pu...mentioning

confidence: 99%

“…Screening should include specific autoantibodies (anti-topoisomerase I (SCL-70), an-ticentromere and anti-RNA polymerase III and antiphospholipid antibodies), pulmonary function tests, echocardiography, pro-terminal brain natriuretic peptide (NT-proBNP), capillaroscopy of nail folds and initial high-resolution CT scan to rule out ILD, and, in case of PAH, right heart catheterization to determine PA pressure [118][119][120][121][122][123][124][125][126]151]. Many molecules have been associated with vascular complications of SSc, so there are many potential biomarkers for vascular disease and PAH in SSc.…”

Section: Biomarkers In Systemic Sclerosis Vascular Injury Focus On Pu...mentioning

confidence: 99%

“…Many molecules have been associated with vascular complications of SSc, so there are many potential biomarkers for vascular disease and PAH in SSc. Activation, endothelial cell apoptosis, specific autoantibodies, infectious agents, reactive oxygen species, and other causes that provide many potential biomarkers may contribute to vascular lesion formation [121][122][123][124][125][126]151]. Once activated, endothelial cells secrete endothelin-1 (ET-1), von Willebrand factor (vWF), nitric oxide, and endothelial nitric oxide synthase, resulting in unstable vascular tone, with decreased vasodilation and increased vasoconstriction causing ischemia and tissue hypoxia [119][120][121][122][123][124].…”

Section: Biomarkers In Systemic Sclerosis Vascular Injury Focus On Pu...mentioning

confidence: 99%

“…Once activated, endothelial cells secrete endothelin-1 (ET-1), von Willebrand factor (vWF), nitric oxide, and endothelial nitric oxide synthase, resulting in unstable vascular tone, with decreased vasodilation and increased vasoconstriction causing ischemia and tissue hypoxia [119][120][121][122][123][124]. Endothelin-1 stimulates fibroblasts to convert to activated myofibroblasts with increased ECM secretion, intimal hyperplasia, luminal narrowing, reduced capillary blood flow vessel obliteration and ischemia [120][121][122][123][124][125][126]151].…”

Section: Biomarkers In Systemic Sclerosis Vascular Injury Focus On Pu...mentioning

confidence: 99%

“…Local secretion of the von Willebrand factor causes platelet aggregation, hypercoagulability, and fibrin deposition leading to terminal vascular injury [126][127][128][129][130][131][132][133]151]. The endothelialmesenchymal transition also favors the formation of myofibroblasts [128][129][130][131][132][133]152,153].…”

Section: Biomarkers In Systemic Sclerosis Vascular Injury Focus On Pu...mentioning

confidence: 99%

See 4 more Smart Citations

Biomarkers in Systemic Sclerosis: An Overview

Di Maggio,

Confalonieri,

Salton

et al. 2023

CIMB

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a complex autoimmune disease characterized by significant fibrosis of the skin and internal organs, with the main involvement of the lungs, kidneys, heart, esophagus, and intestines. SSc is also characterized by macro- and microvascular damage with reduced peripheral blood perfusion. Several studies have reported more than 240 pathways and numerous dysregulation proteins, giving insight into how the field of biomarkers in SSc is still extremely complex and evolving. Antinuclear antibodies (ANA) are present in more than 90% of SSc patients, and anti-centromere and anti-topoisomerase I antibodies are considered classic biomarkers with precise clinical features. Recent studies have reported that trans-forming growth factor β (TGF-β) plays a central role in the fibrotic process. In addition, interferon regulatory factor 5 (IRF5), interleukin receptor-associated kinase-1 (IRAK-1), connective tissue growth factor (CTGF), transducer and activator of transcription signal 4 (STAT4), pyrin-containing domain 1 (NLRP1), as well as genetic factors, including DRB1 alleles, are implicated in SSc damage. Several interleukins (e.g., IL-1, IL-6, IL-10, IL-17, IL-22, and IL-35) and chemokines (e.g., CCL 2, 5, 23, and CXC 9, 10, 16) are elevated in SSc. While adiponectin and maresin 1 are reduced in patients with SSc, biomarkers are important in research but will be increasingly so in the diagnosis and therapeutic approach to SSc. This review aims to present and highlight the various biomarker molecules, pathways, and receptors involved in the pathology of SSc.

show abstract

Section: Biomarkers In Systemic Sclerosis Vascular Injury Focus On Pu...mentioning

confidence: 99%

Section: Biomarkers In Systemic Sclerosis Vascular Injury Focus On Pu...mentioning

confidence: 99%

Section: Biomarkers In Systemic Sclerosis Vascular Injury Focus On Pu...mentioning

confidence: 99%

Section: Biomarkers In Systemic Sclerosis Vascular Injury Focus On Pu...mentioning

confidence: 99%

Section: Biomarkers In Systemic Sclerosis Vascular Injury Focus On Pu...mentioning

confidence: 99%

See 3 more Smart Citations

Biomarkers in Systemic Sclerosis: An Overview

Di Maggio,

Confalonieri,

Salton

et al. 2023

CIMB

View full text Add to dashboard Cite

show abstract

Metabolomics in systemic sclerosis

Gogulska,

Smolenska,

Turyn

et al. 2024

Rheumatol Int

View full text Add to dashboard Cite

Systemic sclerosis is a rare autoimmune condition leading to incurable complications. Therefore fast and precise diagnosis is crucial to prevent patient death and to maintain quality of life. Unfortunately, currently known biomarkers do not meet this need. To address this problem researchers use diverse approaches to elucidate the underlying aberrations. One of the methods applied is metabolomics. This modern technique enables a comprehensive assessment of multiple compound concentrations simultaneously. As it has been gaining popularity, we found it necessary to summarize metabolomic studies presented so far in a narrative review. We found 11 appropriate articles. All of the researchers found significant differences between patients and control groups, whereas the reported findings were highly inconsistent. Additionally, we have found the investigated groups in most studies were scarcely described, and the inclusion/exclusion approach was diverse. Therefore, further study with meticulous patient assessment is necessary.

show abstract

Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis

Muruganandam,

Ariza-Hutchinson,

Patel

et al. 2023

JIR

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a complex autoimmune disease characterized by vascular damage, vasoinstability, and decreased perfusion with ischemia, inflammation, and exuberant fibrosis of the skin and internal organs. Biomarkers are analytic indicators of the biological and disease processes within an individual that can be accurately and reproducibly measured. The field of biomarkers in SSc is complex as recent studies have implicated at least 240 pathways and dysregulated proteins in SSc pathogenesis. Anti-nuclear antibodies (ANA) are classical biomarkers with well-described clinical classifications and are present in more than 90% of SSc patients and include anti-centromere, anti-Th/To, anti-RNA polymerase III, and anti-topoisomerase I antibodies. Transforming growth factor-β (TGF-β) is central to the fibrotic process of SSc and is intimately intertwined with other biomarkers. Tyrosine kinases, interferon-1 signaling, IL-6 signaling, endogenous thrombin, peroxisome proliferator-activated receptors (PPARs), lysophosphatidic acid receptors, and amino acid metabolites are new biomarkers with the potential for developing new therapeutic agents. Other biomarkers implicated in SSc-ILD include signal transducer and activator of transcription 4 (STAT4), CD226 (DNAX accessory molecule 1), interferon regulatory factor 5 (IRF5), interleukin-1 receptor–associated kinase-1 (IRAK1), connective tissue growth factor (CTGF), pyrin domain containing 1 (NLRP1), T-cell surface glycoprotein zeta chain (CD3ζ) or CD247, the NLR family, SP-D (surfactant protein), KL-6, leucine-rich α2-glycoprotein-1 (LRG1), CCL19, genetic factors including DRB1 alleles, the interleukins (IL-1, IL-4, IL-6, IL-8, IL-10 IL-13, IL-16, IL-17, IL-18, IL-22, IL-32, and IL-35), the chemokines CCL (2,3,5,13,20,21,23), CXC (8,9,10,11,16), CX3CL1 (fractalkine), and GDF15. Adiponectin (an indicator of PPAR activation) and maresin 1 are reduced in SSc patients. A new trend has been the use of biomarker panels with combined complex multifactor analysis, machine learning, and artificial intelligence to determine disease activity and response to therapy. The present review is an update of the various biomarker molecules, pathways, and receptors involved in the pathology of SSc.

show abstract

Serum metabolite differences detected by HILIC UHPLC-Q-TOF MS in systemic sclerosis

Cited by 5 publications

References 27 publications

Biomarkers in Systemic Sclerosis: An Overview

Biomarkers in Systemic Sclerosis: An Overview

Metabolomics in systemic sclerosis

Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis

Contact Info

Product

Resources

About